GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (XSWX:IDIA) » Definitions » Research & Development

Idorsia (XSWX:IDIA) Research & Development : CHF170.02 Mil (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Idorsia's Research & Development for the three months ended in Sep. 2024 was CHF40.07 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was CHF170.02 Mil.

Idorsia Research & Development Historical Data

The historical data trend for Idorsia's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Research & Development Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 438.53 381.08 414.21 383.33 293.56

Idorsia Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.93 59.06 32.81 38.07 40.07

Idorsia Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF170.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idorsia  (XSWX:IDIA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Idorsia Research & Development Related Terms

Thank you for viewing the detailed overview of Idorsia's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Idorsia Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (XSWX:IDIA) » Definitions » Research & Development
Comparable Companies
XSWX:XLS XSWX:BSLN XSWX:SANN XSWX:MOLN XSWX:NWRN XSWX:RLF XSWX:EVE XSWX:SPEX XSWX:OBSN XSWX:ADXN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IDRSF:USA IDIAz:UK 0RQE:UK
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Website
https://www.idorsia.com
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia Headlines

No Headlines